Darmiyan
Precision brain health screening and monitoring company using medical AI and brain imaging software to detect neurodegenerative disease at early stages.
About Darmiyan
Novel quantitative virtual microscopy for early detection of Alzheimer's disease from non-invasive MRI.
Industries served
Products
First FDA-approved medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI) by combining a patien...
What customers say
“As a member of the research team that evaluated Darmiyan’s solution for predicting conversion of cognitive impairment to Alzheimer’s dementia, I was impressed by the potential of this breakthrough technology. All study investigators are optimistic that the solution will be successful providing a much needed predictor of disease progression. It may therefore fill a significant diagnostic gap highly valued by patients, clinicians, and clinical researchers.”
“I am the PI of a longitudinal Brain Aging Study at HMRI for more than ten years. Our goal is to identify prodromal biomarkers and potential mechanisms of early dementia pathology of the Alzheimer type. Objective measures such as Darmiyan’s BrainSee that can predict cognitive decline are strongly needed to recognize and monitor potential therapies. I have interacted with Darmiyan for over two years, sharing some of the data from our Brain Aging study participants. I am excited by the potential for objective ways such as Darmiyan’s approach to predict cognitive decline, which can lead to better outcomes for patients and the healthcare system.”
“Darmiyan’s AI, machine learning algorithm using unique MRI microscopic pixel analysis with macroscopic input has generated a very sensitive and specific five year prognosis for patients presenting with amnestic MCI. This technology has high test retest reliability and can be applied to any clinical grade MRI which is a very useful clinical tool to assist doctors advising patients with early memory complaints. In addition the BrainSee degeneration maps clearly show focal areas of degeneration. I believe this will be a widely used technology to assist doctors and patients navigating the difficult terrain of MCI.”
Security and compliance
As reported by Darmiyan. Ask for audit reports before you buy.
- FDA De Novo ApprovalCompliant
- FDA Breakthrough DesignationCompliant
Is this your company?
Claim the profile to keep facts current, answer buyers and submit evidence for the next ranking review.
Claim Darmiyan